ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning. ROME was launched in April 2020 and was incubated at GV, in collaboration with ARCH Venture Partners and Partners Innovation Fund. ROME is based in Cambridge, Mass. For more information, please visit www.rometx.com.
Company Details
- Employees
- 36
- Founded
- -
- Address
- 201 Brookline Ave, Boston,massachusetts 02215,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- rometx.com
- HQ
- Boston, Massachusetts
Rome Therapeutics Questions
Rome Therapeutics's website is rometx.com
Rome Therapeutics's LinkedIn profile is https://www.linkedin.com/company/rome-therapeutics
Rome Therapeutics has
36 employees.
View email and phone details for 36
employees at Rome Therapeutics.
Rome Therapeutics's industry is
Biotechnology Research
Rome Therapeutics's top competitors are
Vidavinci, Inc.,
Enara Bio,
Nimbus Therapeutics,
Pretzel Therapeutics,
Tessera Therapeutics,
Apollo Therapeutics,
Rapport Therapeutics,
Nucleome Therapeutics,
Beam Therapeutics,
Kymera Therapeutics.
Rome Therapeutics's categories are Biotechnology Research
Rome Therapeutics's founding year is 2020
